Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Points for proteins are counted because the product is considered to be a beverage
Imfinzi (durvalumab) Disease area(s): Oncology Manufacturer(s): AstraZeneca 2024 Sales (USD): $4.72 billion Why it sold so well: In 2024, AstraZenecas Imfinzi experienced strong sales growth, driven by expanded indications and robust clinical trial results
Key contributors to neuromuscular dysfunction and muscle loss associated with aging Sarcopenia exhibits substantial variability, shaped by genetic, environmental, and epigenetic influences [6]
These insights should be interpreted with a qualified healthcare provider to personalize dosing strategies
Springer Singapore, Singapore, pp 14
Tirzepatide offers superior weight loss results through dual hormone receptor activation, while Qsymia provides appetite suppression through neurotransmitter modulation at a lower cost
US$ 26.59
US$ 28.43
US$ 29.14
US$ 24.39
